| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10900003 | Cancer Letters | 2013 | 9 Pages |
Abstract
⺠KRC-408 is a novel triazolopyridazine derivative that targets the catalytic activity of c-Met. ⺠KRC-408 has a significant effect on cancer cells expressing c-Met by blocking the c-Met signaling pathway. ⺠KRC-408 inhibited cell proliferation, angiogenesis as well as induction of apoptosis in cases of gastric cancer. ⺠KRC-408 is a novel therapeutic candidate effective against gastric cancers that overexpress c-Met.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sang-Won Hong, Kyung-Hee Jung, Byung Hee Park, Hong-Mei Zheng, Hee-Seung Lee, Myung-Joo Choi, Jeong In Yun, Nam Sook Kang, Jongkook Lee, Soon-Sun Hong,